Press release
Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Analysis | Latest FDA, EMA, and PMDA Approvals | Oncotelic, Jiangsu Hengrui MedicineCo, Bristol-MyersSquibb, Rigel., BiogenIdec, Genentech, TilosTherapeutics, Eli Lilly and Company
"Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Transforming Growth Factor Beta (TGFb) Inhibitor Market.
The Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Report: https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Transforming Growth Factor Beta (TGFb) Inhibitor treatment therapies with a considerable amount of success over the years.
• Transforming Growth Factor Beta (TGFb) Inhibitor companies working in the treatment market are Laekna Therapeutics, Sonnet Biotherapeutic, KaliVir Immunotherapeu tics, Isarna Therapeutics, Bristol-Myers Squibb, Acceleron Pharma Inc., Huabo Biopharm, Keros Therapeutics, Novartis Pharmaceutical, Merck Sharp & Dohme LLC, Jiangsu Hengrui Medicine, and others, are developing therapies for the Transforming Growth Factor Beta (TGFb) Inhibitor treatment
• Emerging Transforming Growth Factor Beta (TGFb) Inhibitor therapies in the different phases of clinical trials are- LAE-106, SON 3015, VET3-TGI, ASPH-1047, BMS 986416, MK-2225, HB002.1T, KER-050, NIS793, MK-7962, SHR 1701, and others are expected to have a significant impact on the Transforming Growth Factor Beta (TGFb) Inhibitor market in the coming years.
• SB-431542 and SB-505124, developed by GlaxoSmithKline, are notable inhibitors of TGF-β receptor kinase currently in the pre-clinical development stage. These inhibitors specifically hinder the phosphorylation of Smad2/3. In MG63 human osteosarcoma cells, the expression of c-myc, a gene typically suppressed by TGF-β in many cell types, was observed to increase. This implies that the upregulation of c-myc expression could potentially be the mechanism through which the inhibitory signals of TGF-β on cell growth are blocked in MG63 cells.
Transforming Growth Factor Beta (TGFb) Inhibitor Overview
Get a Free Sample PDF Report to know more about Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Transforming Growth Factor Beta (TGFb) Inhibitor Drugs Under Different Phases of Clinical Development Include:
• LAE-106: Laekna Therapeutics
• SON 3015: Sonnet Biotherapeutic
• VET3-TGI: KaliVir Immunotherapeu tics
• ASPH-1047: Isarna Therapeutics
• BMS 986416: Bristol-Myers Squibb
• MK-2225: Acceleron Pharma Inc.
• HB002.1T: Huabo Biopharm
• KER-050: Keros Therapeutics
• NIS793: Novartis Pharmaceutical
• MK-7962: Merck Sharp & Dohme LLC
• SHR 1701: Jiangsu Hengrui Medicine
Transforming Growth Factor Beta (TGFb) Inhibitor Route of Administration
Transforming Growth Factor Beta (TGFb) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Transforming Growth Factor Beta (TGFb) Inhibitor Molecule Type
Transforming Growth Factor Beta (TGFb) Inhibitor Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Therapeutics Assessment
• Transforming Growth Factor Beta (TGFb) Inhibitor Assessment by Product Type
• Transforming Growth Factor Beta (TGFb) Inhibitor By Stage and Product Type
• Transforming Growth Factor Beta (TGFb) Inhibitor Assessment by Route of Administration
• Transforming Growth Factor Beta (TGFb) Inhibitor By Stage and Route of Administration
• Transforming Growth Factor Beta (TGFb) Inhibitor Assessment by Molecule Type
• Transforming Growth Factor Beta (TGFb) Inhibitor by Stage and Molecule Type
DelveInsight's Transforming Growth Factor Beta (TGFb) Inhibitor Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Transforming Growth Factor Beta (TGFb) Inhibitor product details are provided in the report. Download the Transforming Growth Factor Beta (TGFb) Inhibitor pipeline report to learn more about the emerging Transforming Growth Factor Beta (TGFb) Inhibitor therapies at:
https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Transforming Growth Factor Beta (TGFb) Inhibitor Therapeutics Market include:
Key companies developing therapies for Transforming Growth Factor Beta (TGFb) Inhibitor are - Oncotelic, Jiangsu Hengrui MedicineCo, Bristol-MyersSquibb, Rigel., BiogenIdec, Genentech, TilosTherapeutics, Eli Lilly and Company, and others.
Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Analysis:
The Transforming Growth Factor Beta (TGFb) Inhibitor pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Transforming Growth Factor Beta (TGFb) Inhibitor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Transforming Growth Factor Beta (TGFb) Inhibitor Treatment.
• Transforming Growth Factor Beta (TGFb) Inhibitor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Transforming Growth Factor Beta (TGFb) Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Transforming Growth Factor Beta (TGFb) Inhibitor market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Transforming Growth Factor Beta (TGFb) Inhibitor drugs and therapies-
https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Market Drivers
• Increase in prevalence of Cancer, emerging as a highly promising, safe and effective anticancer agent are some of the important factors that are fueling the Transforming Growth Factor Beta (TGFb) Inhibitor Market.
Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Market Barriers
• However, high cost associated with the treatment, limited understanding of the dual role of TGF-β as a tumor suppressor and tumor promoter in cancer and other factors are creating obstacles in the Transforming Growth Factor Beta (TGFb) Inhibitor Market growth.
Scope of Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Drug Insight
• Coverage: Global
• Key Transforming Growth Factor Beta (TGFb) Inhibitor Companies: Laekna Therapeutics, Sonnet Biotherapeutic, KaliVir Immunotherapeu tics, Isarna Therapeutics, Bristol-Myers Squibb, Acceleron Pharma Inc., Huabo Biopharm, Keros Therapeutics, Novartis Pharmaceutical, Merck Sharp & Dohme LLC, Jiangsu Hengrui Medicine, and others
• Key Transforming Growth Factor Beta (TGFb) Inhibitor Therapies: LAE-106, SON 3015, VET3-TGI, ASPH-1047, BMS 986416, MK-2225, HB002.1T, KER-050, NIS793, MK-7962, SHR 1701, and others
• Transforming Growth Factor Beta (TGFb) Inhibitor Therapeutic Assessment: Transforming Growth Factor Beta (TGFb) Inhibitor current marketed and Transforming Growth Factor Beta (TGFb) Inhibitor emerging therapies
• Transforming Growth Factor Beta (TGFb) Inhibitor Market Dynamics: Transforming Growth Factor Beta (TGFb) Inhibitor market drivers and Transforming Growth Factor Beta (TGFb) Inhibitor market barriers
Request for Sample PDF Report for Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Transforming Growth Factor Beta (TGFb) Inhibitor Report Introduction
2. Transforming Growth Factor Beta (TGFb) Inhibitor Executive Summary
3. Transforming Growth Factor Beta (TGFb) Inhibitor Overview
4. Transforming Growth Factor Beta (TGFb) Inhibitor- Analytical Perspective In-depth Commercial Assessment
5. Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Therapeutics
6. Transforming Growth Factor Beta (TGFb) Inhibitor Late Stage Products (Phase II/III)
7. Transforming Growth Factor Beta (TGFb) Inhibitor Mid Stage Products (Phase II)
8. Transforming Growth Factor Beta (TGFb) Inhibitor Early Stage Products (Phase I)
9. Transforming Growth Factor Beta (TGFb) Inhibitor Preclinical Stage Products
10. Transforming Growth Factor Beta (TGFb) Inhibitor Therapeutics Assessment
11. Transforming Growth Factor Beta (TGFb) Inhibitor Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Transforming Growth Factor Beta (TGFb) Inhibitor Key Companies
14. Transforming Growth Factor Beta (TGFb) Inhibitor Key Products
15. Transforming Growth Factor Beta (TGFb) Inhibitor Unmet Needs
16 . Transforming Growth Factor Beta (TGFb) Inhibitor Market Drivers and Barriers
17. Transforming Growth Factor Beta (TGFb) Inhibitor Future Perspectives and Conclusion
18. Transforming Growth Factor Beta (TGFb) Inhibitor Analyst Views
19. Appendix
20. About DelveInsight
Latest Reports:
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of heart failure and cardiovascular diseases due to obesity, age, & unhealthy lifestyles and rising demand for organ transplants due to increasing prevalence of chronic ailments such as hypertension, diabetes, and others
B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.
Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.
Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.
Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.
Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.
Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Transforming Growth Factor Beta (TGFb) Inhibitor Pipeline Analysis | Latest FDA, EMA, and PMDA Approvals | Oncotelic, Jiangsu Hengrui MedicineCo, Bristol-MyersSquibb, Rigel., BiogenIdec, Genentech, TilosTherapeutics, Eli Lilly and Company here
News-ID: 3349899 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Transforming
Transforming Lives , Together
Unessa Foundation is a purpose-driven organization committed to transforming lives, together. Built on the belief that unity and compassion are the cornerstones of meaningful change, Unessa empowers individuals and communities through inclusive programs, collaborative efforts, and a people-first approach.
Rooted in dignity, empathy, and impact, our mission is to uplift underrepresented voices, close opportunity gaps, and strengthen human connections that create lasting social change. At Unessa, we see every person as…
Exosome Innovations Transforming Healthcare Solutions
The global exosome diagnostic and therapeutic market is witnessing remarkable growth, with its projected value reaching an astounding USD 22,609.77 million by 2034, up from USD 33.04 million in 2023. This meteoric rise represents a staggering compound annual growth rate (CAGR) of 81.03% from 2024 to 2034. As the market continues to expand, the spotlight is firmly on exosomes, small extracellular vesicles that play a significant role in a variety…
ADC Market: Transforming Cancer Treatment
The global market for antibody-drug conjugates (ADCs) was valued at US$ 11.32 billion in 2023 and is expected to reach US$ 27.37 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.23% from 2024 to 2033. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for safe and effective treatments.
Antibody Drug Conjugates: A Growing Force in Cancer Treatment and Market Expansion
Key…
Transforming Higher Education Admissions
Radius X, a user-friendly platform for admission automation and data analysis, is now available for higher education providers. Designed to simplify the admissions process, Radius X enhances the student experience through self-service options and automation.
Admissions teams today face growing challenges as they handle more applications and higher expectations from students. Many are overwhelmed by paperwork and manual tasks that take away valuable time. Radius X addresses these struggles by…
Curiotory: Transforming Language Learning
India's ultimate language learning app
Curiotory is a language learning platform dedicated to creating an enjoyable and effective learning experience. With a focus on online language learning, Curiotory empowers learners to achieve fluency and cultural understanding.
Curiotory, a trailblazer in the language learning industry, is proud to announce its continued commitment to providing a unique, immersive, and personalized approach to language education. With a mission to bridge cultural gaps and make…
Transforming Smiles, Transforming Lives: Introducing Dr. Robert Rifkin, the Maes …
Image: https://www.getnews.info/uploads/3cc5ecdc456666ed434d2b2f5410c024.png
Dr. Robert Rifkin, the visionary force behind some of the most iconic smiles worldwide, continues to redefine the standards of cosmetic dentistry. With over four decades of unparalleled expertise, Dr. Rifkin has earned his place as the godfather of cosmetic dentistry, revolutionizing the field with his innovative treatments and unparalleled artistry.
A Legacy of Innovation
For over 40 years, Dr. Robert Rifkin has been at the forefront of cosmetic dentistry in…
